Extending qualified research institutions beyond the investigational new drug application

To renew US competitiveness in clinical trials, the federal government launched Operation TrialBlazer in June 2026. Its proposed Expedited-IND Acceleration Pilot would enlist Qualified Research Institutions (QRIs) to help sponsors prepare investigational new drug (IND) applications for first-in-human studies. Because a successful IND does not guarantee a completed trial, we propose a testable, expanded QRI framework to support trial execution. First, build QRIs with standing networks that reuse contracts, data systems, and staff to lower marginal costs and enable performance measurement. Second, require QRIs to have capabilities that enable and assess site performance: human factors expertise and stakeholder co-design in protocol development; leading (not only lagging) indicators of trial performance; efficient, proportionate execution that preserves rigor and safety; and oversight by an independent trial performance monitoring board empowered to conduct in-person observations and interviews at trial sites. Third, qualify QRIs on demonstrated performance, with reciprocal obligations for sponsors. Fourth, renew QRIs using publicly reported, case-mix-adjusted metrics. The Food and Drug Administration and National Institutes of Health should jointly fund evaluations of this framework. Extending QRIs across the trial lifecycle is more likely than a pre-IND role alone to close the time and cost gaps that send research overseas.

Authors

Institutions

Publication Details

Journal
Journal of Clinical and Translational Science
Published
2026-11-19
DOI
https://doi.org/10.1017/cts.2026.10861
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Extending qualified research institutions beyond the investigational new drug application

Jerry A. Krishnan, Scott M. Palmer, Rajiv Advani, Hugh R. Musick
Journal of Clinical and Translational Science
Ethics in Clinical Research
article

Extending qualified research institutions beyond the investigational new drug application

Jerry A. Krishnan, Scott M. Palmer, Rajiv Advani, Hugh R. Musick
article en

Abstract

To renew US competitiveness in clinical trials, the federal government launched Operation TrialBlazer in June 2026. Its proposed Expedited-IND Acceleration Pilot would enlist Qualified Research Institutions (QRIs) to help sponsors prepare investigational new drug (IND) applications for first-in-human studies. Because a successful IND does not guarantee a completed trial, we propose a testable, expanded QRI framework to support trial execution. First, build QRIs with standing networks that reuse contracts, data systems, and staff to lower marginal costs and enable performance measurement. Second, require QRIs to have capabilities that enable and assess site performance: human factors expertise and stakeholder co-design in protocol development; leading (not only lagging) indicators of trial performance; efficient, proportionate execution that preserves rigor and safety; and oversight by an independent trial performance monitoring board empowered to conduct in-person observations and interviews at trial sites. Third, qualify QRIs on demonstrated performance, with reciprocal obligations for sponsors. Fourth, renew QRIs using publicly reported, case-mix-adjusted metrics. The Food and Drug Administration and National Institutes of Health should jointly fund evaluations of this framework. Extending QRIs across the trial lifecycle is more likely than a pre-IND role alone to close the time and cost gaps that send research overseas.

Journal of Clinical and Translational ScienceVol. 10(1)
Duke University (US), University of Illinois Chicago (US), Duke Medical Center (US)
Ethics in Clinical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon